Provided by Tiger Fintech (Singapore) Pte. Ltd.

Stoke Therapeutics, Inc.

8.60
+0.49006.04%
Post-market: 8.600.00000.00%18:17 EDT
Volume:876.96K
Turnover:7.50M
Market Cap:455.52M
PE:-4.16
High:8.72
Open:8.18
Low:8.18
Close:8.11
Loading ...

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

Business Wire
·
07 Jan

The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex

Zacks
·
26 Dec 2024

4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

Zacks
·
25 Dec 2024

Chardan Initiates Coverage on Stoke Therapeutics With Buy Rating

MT Newswires Live
·
20 Dec 2024

Stoke Therapeutics initiated with a Buy at Chardan

TIPRANKS
·
20 Dec 2024

Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth

Simply Wall St.
·
17 Dec 2024

Stoke Therapeutics (NASDAQ:STOK) pulls back 9.1% this week, but still delivers shareholders solid 136% return over 1 year

Simply Wall St.
·
14 Dec 2024

Analysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Kura Oncology (KURA)

TIPRANKS
·
10 Dec 2024

Analysts’ Top Healthcare Picks: Stoke Therapeutics (STOK), Beam Therapeutics (BEAM)

TIPRANKS
·
09 Dec 2024

Stoke Therapeutics Reports Durable Seizure Control With Zorevunersen in Dravet Patient

MT Newswires Live
·
07 Dec 2024

Stoke reports ‘substantial’ reductions in seizure frequency with zorevunersen

TIPRANKS
·
07 Dec 2024

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Business Wire
·
07 Dec 2024

STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug

Zacks
·
05 Dec 2024

GeneDx expands access to exome testing for pediatric epilepsy patients

TIPRANKS
·
05 Dec 2024

BUZZ-Stoke rises on FDA's 'breakthrough therapy' tag for epileptic disorder drug

Reuters
·
05 Dec 2024

Stoke Therapeutics' Zorevunersen Gets FDA Breakthrough Therapy Status in Dravet Syndrome

MT Newswires Live
·
04 Dec 2024